Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polidocanol pharyngeal sclerotherapy for obstructive sleep apnea syndrome and snoring
ACTRN12606000444583Phase 2Not yet recruiting
- Sponsor
- Youliang Yin
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 10XB101 in obstructive sleep apnea hypopnea syndrome (OSAHS) and primary snoring, sponsored by Youliang Yin. Primary endpoints: Apnea-hypopnea index and Anterior-posterior treatment comparison in 2 years. Planned start Dec 2006; status: not yet recruiting.
02
Drugs
10XB101
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)primary snoring
Beyond the preview
Go deeper on ACTRN12606000444583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000444583.